2030년까지의 남미 및 중미 간질 시장 전망 - 지역 분석 - 유형별(진행성 근간대성 간질, 반사성 간질, 전신성 간질 및 기타), 투여 경로(경구, 비경구 및 기타), 치료 유형(1세대 약물, 2세대 약물 및 3세대 약물), 연령대(성인 및 어린이), 유통 채널(병원 약국, 소매 약국 및 기타)

BMIRE00030802 | Pages: 136 | Pharmaceuticals | Sep 2024 | Type: Regional | Status: Published
남미 및 중미 간질 시장은 2022년에 5억 9,356만 달러 규모였으며 2030년까지 7억 5,865만 달러에 도달할 것으로 예상되며 2022년에서 2030년까지 연평균 성장률 3.1%를 기록할 것으로 추산됩니다.

기관에서 실시하는 인식 제고 프로그램의 급증으로 남미 및 중미 간질 시장이 활성화됨

간질, 간질 증상 및 조기 진단의 중요성에 대한 인식이 높아짐에 따라 의료 지원을 찾는 환자가 급증했습니다. Epilepsy Foundation, Epilepsy Society, American Epilepsy Society, Epilepsy Association of Central Florida와 같은 기관은 이 질병에 대한 교육을 제공하는 데 중요한 역할을 합니다. 이러한 기관의 참여로 진단율이 증가하고 간질 치료가 필요한 환자 집단이 확대되었습니다. 전 세계적으로 기관에서 수많은 인식 제고 캠페인을 실시하여 이 질환과 이용 가능한 치료법에 대한 인식을 확산하고 있습니다. 브라질에서 브라질 간질 연맹(LBE)은 간질 인식의 달 동안 전국적인 인식 캠페인을 실시합니다. 그들은 이벤트를 조직하고, 교육 자료를 배포하고, 미디어와 협력하여 간질에 대한 인식을 높이고 낙인을 줄입니다. 따라서 이러한 이니셔티브와 인식 캠페인은 간질 진단 및 치료의 증가로 이어져 시장에 수익성 있는 성장 기회를 제공합니다.

남미 및 중미 간질 시장 개요

남미 및 중미의 간질 시장에는 브라질, 아르헨티나, 그리고 나머지 남미 및 중미에 대한 국가 수준 분석이 포함됩니다. 브라질은 이 지역에서 상당한 시장 점유율을 가질 것으로 예상됩니다. 범미 보건 기구에 따르면 라틴 아메리카, 남미 및 카리브해 지역에 치료 격차가 있습니다. 즉, 50%가 넘습니다. 최근 몇 년 동안 국가들은 간질을 포함한 비전염성 질환에 대한 집중을 강화했습니다. 2023년에 발간된 International Journal of Public Health 기사에 따르면, 2019년에 남미 및 중앙아메리카 국가에서 총 1,375,066의 장애 조정 생명 연수(DALY)가 간질에 기인한 것으로 나타났으며, 남성이 더 많은 영향을 받는 것으로 나타났습니다.

남미 및 중앙아메리카 간질 시장 수익 및 2030년 예측(백만 달러)

남미 및 중앙아메리카 간질 시장 세분화

남미 및 중앙아메리카 간질 시장은 유형, 투여 경로, 치료 유형, 연령대, 유통 채널 및 국가로 분류됩니다.

유형을 기준으로 남미 및 중앙아메리카 간질 시장은 진행성 근간대성 간질, 반사성 간질, 전신성 간질 및 기타로 분류됩니다. 일반화된 간질 분야는 2022년에 가장 큰 시장 점유율을 차지했습니다.

투여 경로 측면에서 남중미 간질 시장은 경구, 비경구 및 기타로 분류됩니다. 경구 분야는 2022년에 가장 큰 시장 점유율을 차지했습니다.

치료 유형별로 남중미 간질 시장은 1세대 약물, 2세대 약물 및 3세대 약물로 세분화됩니다. 3세대 약물 분야는 2022년에 가장 큰 시장 점유율을 차지했습니다.

연령대에 따라 남중미 간질 시장은 성인과 어린이로 나뉩니다. 성인 분야는 2022년에 더 큰 시장 점유율을 차지했습니다.

유통 채널 측면에서 남중미 간질 시장은 병원 약국, 소매 약국 및 기타로 분류됩니다. 병원 약국 부문은 2022년에 가장 큰 시장 점유율을 차지했습니다.

국가별로 남중미 간질 시장은 브라질, 아르헨티나, 그리고 남중미의 나머지 지역으로 세분화됩니다. 브라질은 2022년에 남중미 간질 시장 점유율을 지배했습니다.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, 그리고 H. Lundbeck AS는 남중미 간질 시장에서 운영되는 몇몇 선도적인 회사들입니다.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches

4.1.1 Cell and Gene Therapy Approaches

4.1.2 Encapsulated cell bio delivery (ECB) system

4.1.3 Gene Therapy for Epilepsy Clinical Overview

4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy

4.1.3.1.1 Gene Supplementation - Overview

4.1.3.1.2 Gene Modulation - Overview

4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview

4.1.3.1.4 Neuropeptides - Overview

4.1.3.1.5 Engineered Channels - Overview

4.1.3.1.6 Endogenous Channels - Overview

4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy

4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy

4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy

4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy

4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview

4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches

4.1.3.6 Potassium Channels for Human Epileptic Phenotypes

4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. South & Central America Epilepsy Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Epilepsy

5.1.2 Increasing Investments in Development of Epilepsy Therapies

5.2 Market Restraints

5.2.1 Recall of Products

5.3 Market Opportunities

5.3.1 Surge in Awareness Programs Conducted by Organizations

5.4 Future Trends

5.4.1 Gene Therapy as Promising Treatment Approach

5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - South & Central America Analysis

6.1 South & Central America: Epilepsy Market

7. South & Central America Epilepsy Market Analysis - by Type

7.1 Overview

7.2 Progressive Myoclonic Epilepsy

7.2.1 Overview

7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Reflex Epilepsy

7.3.1 Overview

7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Generalized Epilepsy

7.4.1 Overview

7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Other

7.5.1 Overview

7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Epilepsy Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Epilepsy Market Analysis - by Treatment Type

9.1 Overview

9.2 First Generation Drugs

9.2.1 Overview

9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Second Generation Drugs

9.3.1 Overview

9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Third Generation Drugs

9.4.1 Overview

9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Epilepsy Market Analysis - by Age Group

10.1 Overview

10.2 Adult

10.2.1 Overview

10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10.3 Children

10.3.1 Overview

10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. South & Central America Epilepsy Market Analysis - by Distribution Channel

11.1 Overview

11.2 Hospital Pharmacies

11.2.1 Overview

11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.4 Others

11.4.1 Overview

11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. South & Central America Epilepsy Market - Country Analysis

12.1 South & Central America Epilepsy Market Overview

12.1.1 South & Central America: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)

12.1.1.1 Brazil: Epilepsy Market Overview

12.1.1.2 Brazil: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.2.1 Brazil: Epilepsy Market Breakdown, by Type

12.1.1.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration

12.1.1.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type

12.1.1.2.4 Brazil: Epilepsy Market Breakdown, by Age Group

12.1.1.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.3 Argentina: Epilepsy Market Overview

12.1.1.4 Argentina: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.4.1 Argentina: Epilepsy Market Breakdown, by Type

12.1.1.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration

12.1.1.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type

12.1.1.4.4 Argentina: Epilepsy Market Breakdown, by Age Group

12.1.1.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.5 Rest of South & Central America: Epilepsy Market Overview

12.1.1.6 Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.6.1 Rest of South & Central America: Epilepsy Market Breakdown, by Type

12.1.1.6.2 Rest of South & Central America: Epilepsy Market Breakdown, by Route of Administration

12.1.1.6.3 Rest of South & Central America: Epilepsy Market Breakdown, by Treatment Type

12.1.1.6.4 Rest of South & Central America: Epilepsy Market Breakdown, by Age Group

12.1.1.6.5 Rest of South & Central America: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview

13.2 Growth Strategies in Epilepsy Market

13.3 Organic Growth Strategies

13.3.1 Overview

13.4 Inorganic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Eisai Co Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 UCB SA

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 LivaNova Plc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Medtronic Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 GSK Plc

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 H. Lundbeck AS

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

 

 

 

List of Tables

Table 1. South & Central America Epilepsy Market Segmentation

Table 2. Cell Therapy Approach - An Overview

Table 3. Gene Therapy Approach - An Overview

Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview

Table 5. Preclinically Tested Genetic Therapies for Epilepsy

Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview

Table 7. Viral Vectors Comparison with respect to Various Parameters

Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies

Table 9. Enzyme-Inducing Antiepileptic Drugs

Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview

Table 11. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 12. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 13. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 14. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 15. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 16. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 17. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 18. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 19. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 20. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 21. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 22. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 23. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 24. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 25. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 26. Recent Organic Growth Strategies in Epilepsy Market

Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market

?

List of Figures

Figure 1. South & Central America Epilepsy Market Segmentation, by Country

Figure 2. Epilepsy Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030

Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)

Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)

Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)

Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)

Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. South & Central America: Epilepsy Market, By Key Country - Revenue (2022) (US$ Million)

Figure 26. South & Central America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Growth Strategies in Epilepsy Market

 

 

?

  1. Abbott Laboratories
  2. Pfizer Inc
  3. Eisai Co Ltd
  4. UCB SA
  5. LivaNova Plc
  6. Novartis AG
  7. Medtronic Plc
  8. GSK Plc
  9. H. Lundbeck AS
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America epilepsy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America epilepsy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440